Treatment Strategy for Parkinsonian Diseases Through Mesenchymal Stem Cells.
10.7599/hmr.2012.32.3.145
- Author:
Hyun Jung PARK
1
;
Phil Hyu LEE
Author Information
1. Department of Neurology and Brain Research Institute, Yonsei University College of Medicine, Severance Biomedical Science Institute, Yonsei University, Seoul, Korea. phisland@chol.net
- Publication Type:Review
- Keywords:
Mesenchymal Stem Cells;
Therapeutics;
Parkinsonian Disorders
- MeSH:
Adult;
Bone Marrow;
Bone Marrow Cells;
Cell Survival;
Chondrocytes;
Disease Progression;
Humans;
Inclusion Bodies;
Lewy Bodies;
Mesenchymal Stromal Cells;
Multiple System Atrophy;
Muscle Fibers, Skeletal;
Neurodegenerative Diseases;
Neurons;
Neuroprotective Agents;
Parkinson Disease;
Parkinsonian Disorders;
Regeneration;
Tissue Therapy
- From:Hanyang Medical Reviews
2012;32(3):145-153
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Parkinsonian diseases including Parkinson's disease (PD) and multiple system atrophy (MSA) are neurodegenerative diseases representative of alpha-synucleinopathies characterized pathologically by alpha-synuclein-abundant Lewy bodies and glial cytoplasmic inclusions, respectively. Cell therapy using mesenchymal stem cells (MSCs) is attractive clinically because these cells are free from ethical and immunological problems. MSCs are present in adult bone marrow and represent <0.01% of all nucleated bone marrow cells. MSCs are multipotent, and differentiation under appropriate conditions into chondrocytes, skeletal myocytes, and neurons has been demonstrated thus far. According to recent studies, the neuroprotective effect of MSCs is mediated by the production of various trophic factors that contribute to functional recovery, neuronal cell survival, and endogenous regeneration of neural tissues. Additionally, MSCs appear to have immunoregulatory properties that can ameliorate the progression of disease. However, the therapeutic use of MSCs as neuroprotectives in PD and MSA has seldom been studied. Here we comprehensively review recent advances in clinical strategies using MSCs in PD and MSA, especially focusing on their neuroprotective properties in preventing or delaying disease progression and therapeutic potential for providing functional recovery.
